SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
SpyGlass Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$24.60+0.60 (+2.50%)
Close on Oct 19, 2026
- Market cap
- $822.61M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$3.55 (−12.61%)past year
Weekly closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $822.61M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.54
- Dividend yield
- –
- Free cash flow yield
- -4.07%
Fundamentals
- Net income
- -$39.87M
- EPS, diluted
- -$17.98
- Free cash flow
- -$33.49M
- Book value per share
- $6.95
- Diluted shares
- 33M
Three years at a glance
Fiscal years 2023 to 2025, USD
Operating income
-$41.45M
Net income
-$39.87M
EPS, diluted
-$17.98
Free cash flow
-$33.49M
Reported period